Schwenkglenks M - Search Results

1

Cost-effectiveness of physical activity interventions in cancer survivors of developed countries: a systematic review.

Gubler-Gut BE, Pöhlmann J, Flatz A, Schwenkglenks M, Rohrmann S. Gubler-Gut BE, et al. Among authors: schwenkglenks m. J Cancer Surviv. 2021 Dec;15(6):961-975. doi: 10.1007/s11764-021-01002-0. Epub 2021 Feb 23. J Cancer Surviv. 2021. PMID: 33624172 Free PMC article. Review.

2

Human epidermal growth factor receptor 2 expression in early breast cancer patients: a Swiss cost-effectiveness analysis of different predictive assay strategies.

Blank PR, Schwenkglenks M, Moch H, Szucs TD. Blank PR, et al. Among authors: schwenkglenks m. Breast Cancer Res Treat. 2010 Nov;124(2):497-507. doi: 10.1007/s10549-010-0862-7. Epub 2010 Apr 3. Breast Cancer Res Treat. 2010. PMID: 20364309

3

KRAS and BRAF mutation analysis in metastatic colorectal cancer: a cost-effectiveness analysis from a Swiss perspective.

Blank PR, Moch H, Szucs TD, Schwenkglenks M. Blank PR, et al. Among authors: schwenkglenks m. Clin Cancer Res. 2011 Oct 1;17(19):6338-46. doi: 10.1158/1078-0432.CCR-10-2267. Epub 2011 Aug 1. Clin Cancer Res. 2011. PMID: 21807639 Free article.

4

Cost-effectiveness of maintenance pemetrexed in patients with advanced nonsquamous-cell lung cancer from the perspective of the Swiss health care system.

Matter-Walstra K, Joerger M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Matter-Walstra K, et al. Among authors: schwenkglenks m. Value Health. 2012 Jan;15(1):65-71. doi: 10.1016/j.jval.2011.08.1737. Epub 2011 Oct 22. Value Health. 2012. PMID: 22264973 Free article.

5

Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.

Blank PR, Filipits M, Dubsky P, Gutzwiller F, Lux MP, Brase JC, Weber KE, Rudas M, Greil R, Loibl S, Szucs TD, Kronenwett R, Schwenkglenks M, Gnant M. Blank PR, et al. Among authors: schwenkglenks m. Pharmacoeconomics. 2015 Feb;33(2):179-90. doi: 10.1007/s40273-014-0227-x. Pharmacoeconomics. 2015. PMID: 25404424 Free PMC article.

6

Palbociclib as a first-line treatment in oestrogen receptor-positive, HER2-negative, advanced breast cancer not cost-effective with current pricing: a health economic analysis of the Swiss Group for Clinical Cancer Research (SAKK).

Matter-Walstra K, Ruhstaller T, Klingbiel D, Schwenkglenks M, Dedes KJ. Matter-Walstra K, et al. Among authors: schwenkglenks m. Breast Cancer Res Treat. 2016 Jul;158(1):51-57. doi: 10.1007/s10549-016-3822-z. Epub 2016 Jun 8. Breast Cancer Res Treat. 2016. PMID: 27277747

7

Cost-effectiveness of primarily surgical versus primarily conservative treatment of acute and subacute radiculopathies due to intervertebral disc herniation from the Swiss perspective.

Ademi Z, Gloy V, Glinz D, Raatz H, Van Stiphout J, Bucher HC, Schwenkglenks M. Ademi Z, et al. Among authors: schwenkglenks m. Swiss Med Wkly. 2016 Dec 5;146:w14382. doi: 10.4414/smw.2016.14382. eCollection 2016. Swiss Med Wkly. 2016. PMID: 27922167 Free article.

8

Cost-effectiveness of low-dose CT screening for lung cancer in a European country with high prevalence of smoking-A modelling study.

Tomonaga Y, Ten Haaf K, Frauenfelder T, Kohler M, Kouyos RD, Shilaih M, Lorez M, de Koning HJ, Schwenkglenks M, Puhan MA. Tomonaga Y, et al. Among authors: schwenkglenks m. Lung Cancer. 2018 Jul;121:61-69. doi: 10.1016/j.lungcan.2018.05.008. Epub 2018 May 26. Lung Cancer. 2018. PMID: 29858029

9

Adaptation of cost-effectiveness analyses to a single country: the case of bariatric surgery for obesity and overweight.

Ademi Z, Tomonaga Y, van Stiphout J, Glinz D, Gloy V, Raatz H, Bucher HC, Schwenkglenks M. Ademi Z, et al. Among authors: schwenkglenks m. Swiss Med Wkly. 2018 Jun 12;148:w14626. doi: 10.4414/smw.2018.14626. eCollection 2018. Swiss Med Wkly. 2018. PMID: 29894556 Free article. Review.

10

A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC).

Panje CM, Dedes KJ, Matter-Walstra K, Schwenkglenks M, Gautschi O, Siano M, Aebersold DM, Plasswilm L, Lupatsch JE; Swiss Group for Clinical Cancer Research (SAKK). Panje CM, et al. Among authors: schwenkglenks m. Radiother Oncol. 2018 Nov;129(2):257-263. doi: 10.1016/j.radonc.2018.07.017. Epub 2018 Aug 10. Radiother Oncol. 2018. PMID: 30104008 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

239 results

Search Page